Article Text

Download PDFPDF

Marked paraneoplastic hypereosinophilia associated with a low-grade, metastatic canine mast cell tumour
  1. Margaret Musser1,
  2. Erika Berger1,
  3. Heather A Flaherty2,
  4. Leslie Fox1 and
  5. Chad M Johannes1
  1. 1 College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
  2. 2 Veterinary Clinical Pathology, Iowa State University, Ames, Iowa, USA
  1. Correspondence to Dr Margaret Musser; mmusser{at}


An 11-year-old, female, spayed labrador retriever was presented to the Iowa State University Oncology Service for evaluation of a rapidly expanding mass located near the right prescapular lymph node. A Patnaik grade I mast cell tumour (mitotic index <3/10 high-power fields) had been completely excised from the right antebrachium five months before presentation. Cytological evaluation of aspirates from the healed incision site and the new mass revealed mast cells with marked eosinophilic infiltration consistent with local recurrence and presumed lymph node metastasis. A complete blood count revealed markedly elevated eosinophils (23.96×103 cells/µl, reference interval 0–0.75). The patient was diagnosed with a histologically low-grade, biologically high-grade cutaneous, metastatic mast cell tumour with paraneoplastic hypereosinophilia. Changes in the magnitude of peripheral hypereosinophilia frequently paralleled tumour response to treatment with multiple antineoplastic agents. Nine months after initiating chemotherapy, treatment was discontinued due to declining quality of life.

  • mast cell tumor
  • canine
  • hypereosinophilia
  • paraneoplastic Syndrome
  • chemotherapy
  • ckit

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors MM contributed to the data collection, analysis of the data and writing of the manuscript. EB contributed to the management of the case, data collection and writing of the manuscript. HAF evaluated the clinical pathology data and contributed to the writing of the manuscript. LF contributed to the management of the case and writing of the manuscript. CMJ contributed to case management, data collection and preparation of the manuscript. All authors reviewed the final version of this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests CMJ is a former employee of Pfizer Animal Health and has served as a member of the Zoetis (formerly Pfizer Animal Health) Oncology Advisory Board and occasionally receives honoraria for these activities.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement This is a descriptive case report and therefore all data generated has been included in the manuscript.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.